Empowered Patient Podcast

Karen Jagoda
  • 4.9 (18)
  • Medicine
  • Updated Daily

Empowered Patient Podcast with Karen Jagoda is a window into the latest innovations in digital health, the changing dynamic between doctors and patients, and the emergence of precision medicine. The show covers such topics as aging in place, innovative uses for wearables and sensors, advances in clinical research, applied genetics, drug development, and challenges for connected health entrepreneurs.

  1. 1h ago

    Accelerating Bipolar Disorder Research to Transform Diagnosis and Treatments with Cara Altimus and Emily Baxi BD2

    Cara Altimus, the CEO of BD², and Emily Baxi, the Program Director of BD²'s Integrated Network, are focused on integrating research and clinical care to improve outcomes for people with bipolar disorder.  They emphasize the gaps in diagnostics and effective treatments and the need to collect comprehensive biological and clinical data to enable a precision medicine approach. Their Integrated Network is a longitudinal, large-scale study that complements their investments in new therapeutics, moving away from a trial-and-error approach to effective interventions for individuals. Cara explains, "When we think about the mission of BD², it's that we're bringing innovators and patients and the world together to drive new discovery, new understanding, and improved outcomes for people with bipolar disorder so that all people with bipolar disorder can thrive. And that thrive piece is critical to what we do. We're not just thinking about how we will change symptom outcomes, but we are thinking about how we engage across the whole life and all of the components of life, with science at the forefront of what we do." Emily elaborates, "I think it's important to acknowledge here that the tools and the technologies that we have today are quite different from even those that we had 20, 15 years ago, and they've really set the stage for how we can bring research and clinical care together. So we didn't have electronic health records in the past. We didn't have the ability to understand both from a phenotype level, meaning, can we understand the biology? Can we understand the clinical trajectory, the course of somebody's illness?" "We just didn't have the same tools to really bring clarity and understanding to that. So one of the reasons we're so excited about the Integrated Network is that it represents a framework where we're bringing those components together so that research and clinical care are really sitting side by side. So, in practice, that looks like a longitudinal cohort study." #BipolarDiscoveries #BipolarDisorder #MentalHealthResearch #PrecisionPsychiatry #LearningHealthSystem #IntegratedCare #Psychiatry #HealthcareInnovation #ClinicalResearch #DataDrivenCare #PopulationHealth bipolardiscoveries.org Download the transcript here

    22 min

  2. 3h ago ·  Bonus

    Vertical AI Integration Addresses Healthcare Workflow Coordination with Sundar Subramanian Zyter TRANSCRIPT

    Sundar Subramanian, CEO of Zyter, points out that the primary issue in healthcare is not a lack of AI intelligence but a failure in AI execution.  He advocates for a vertical AI integration approach that solves entire domain-specific workflows rather than horizontal or point solutions that automate existing, often inefficient processes. To ensure safe and effective use of AI, implement guardrails that promote transparency and augment clinicians by reducing friction, helping reduce errors, and building trust. Sundar explains, "You see a lot of AI companies around, but when you look at healthcare, especially the problem we have in healthcare, it is actually not an AI intelligence problem. What we have is an AI execution problem. The models are really growing fast and can do all kinds of tasks, but if you look at healthcare and the overall healthcare economy, trillions of dollars are still spent on lots of manual processes because doing things at scale and executing things at scale is not easy. And so Zyter is a company that's trying to solve that problem, which is really how do you coordinate and execute workflows end-to-end safely, transparently, and with humans trusting it and still in control. And so that's what we intend to do and are doing at Zyter."   "So what we mean by that is that problems get solved at the domain level. And when you solve problems at the domain level, it's not a single decision problem. You can embed horizontal tools to enable convenience and do things slightly better than they are today by embedding point solutions, and lots of platforms can help do that. But when you solve for a domain workflow end-to-end, you need a lot of domain intelligence. You need to understand how the regulatory context works. You need to understand how policies and the governance of those policies need to be done. So it's not a single decision problem. And to do that, you need to orchestrate across lots of tools and data that span many domains to solve for outcomes like healthcare access, total cost of care, or quality." #ZyterAI #AIinHealthcare #HealthIT #ClinicalWorkflow #DigitalHealth #HealthcareInnovation #CareDelivery #HealthSystems #Payers #ValueBasedCare Zyter.ai Listen to the podcast here

  3. 3h ago

    Vertical AI Integration Addresses Healthcare Workflow Coordination with Sundar Subramanian Zyter

    Sundar Subramanian, CEO of Zyter, points out that the primary issue in healthcare is not a lack of AI intelligence but a failure in AI execution.  He advocates for a vertical AI integration approach that solves entire domain-specific workflows rather than horizontal or point solutions that automate existing, often inefficient processes. To ensure safe and effective use of AI, implement guardrails that promote transparency and augment clinicians by reducing friction, helping reduce errors, and building trust. Sundar explains, "You see a lot of AI companies around, but when you look at healthcare, especially the problem we have in healthcare, it is actually not an AI intelligence problem. What we have is an AI execution problem. The models are really growing fast and can do all kinds of tasks, but if you look at healthcare and the overall healthcare economy, trillions of dollars are still spent on lots of manual processes because doing things at scale and executing things at scale is not easy. And so Zyter is a company that's trying to solve that problem, which is really how do you coordinate and execute workflows end-to-end safely, transparently, and with humans trusting it and still in control. And so that's what we intend to do and are doing at Zyter."   "So what we mean by that is that problems get solved at the domain level. And when you solve problems at the domain level, it's not a single decision problem. You can embed horizontal tools to enable convenience and do things slightly better than they are today by embedding point solutions, and lots of platforms can help do that. But when you solve for a domain workflow end-to-end, you need a lot of domain intelligence. You need to understand how the regulatory context works. You need to understand how policies and the governance of those policies need to be done. So it's not a single decision problem. And to do that, you need to orchestrate across lots of tools and data that span many domains to solve for outcomes like healthcare access, total cost of care, or quality." #ZyterAI #AIinHealthcare #HealthIT #ClinicalWorkflow #DigitalHealth #HealthcareInnovation #CareDelivery #HealthSystems #Payers #ValueBasedCare Zyter.ai Download the transcript here

    22 min

  4. 1d ago ·  Bonus

    Biofield Therapy Shown to Reduce Pancreatic Cancer Cell Growth and Metastasis with Dr. Lorenzo Cohen UT MD Anderson Cancer Center TRANSCRIPT

    Dr. Lorenzo Cohen, Director of the Integrative Medicine Program at The University of Texas MD Anderson Cancer Center. He's also co-lead author of a study on whether biofield therapy can impact pancreatic cancer. The study demonstrated that biofield therapy could decrease cancer cell proliferation, disrupt mitochondrial function, and reduce metastasis in both cell cultures and animal models, with results comparable to chemotherapy without the side effects. He highlights the challenges to the wider acceptance of this therapy, given the lack of understanding of its mechanism of action and awareness about this growing area of integrative medicine. Lorenzo explains, "So biofield therapies fall into this category of, let's call them treatment modalities in the field of integrative medicine. So integrative medicine can be things like acupuncture, massage, yoga, meditation, nutrition counseling, exercise, things that you could say fall outside of the conventional traditional medical treatments that are within hospital systems. Now, integrative medicine as a whole and integrative oncology in particular have had a huge uptake in hospital systems because of the evidence base in those areas that I just described. The one area that probably remains the most controversial is this area of biofield therapies or often known as energy medicine. I don't actually really like using the term energy medicine because that implies that we know it has something to do with energy, and we're actually not sure exactly what the mechanism is of these therapies. And so what are these? So many of the listeners will have heard of things like Reiki, healing touch, or therapeutic touch."   "External Qigong falls into this category. These are modalities where a practitioner has been trained to be able to work with their own consciousness or their own intention, potentially the biofield of their body. And it is not controversial to know that we as human beings are energetic beings, and we actually do emit biophotons by the nature of being human. But the controversial part is that they are doing that towards a target, whether that be a human being, or, in our case, cells or animals in a laboratory.  And we, in particular, worked with a biofield therapy called the Bengston Cycling Method." #MDAnderson #IntegrativeOncology #BiofieldTherapy #PancreaticCancer #Metastasis #FOXM1 #Mitochondria #PreclinicalResearch #EnergyMedicine #OncologyResearch.  Biofield Therapy Anticancer Living: Transform Your Life and Health with the Mix of Six Listen to the podcast here

  5. 1d ago

    Biofield Therapy Shown to Reduce Pancreatic Cancer Cell Growth and Metastasis with Dr. Lorenzo Cohen UT MD Anderson Cancer Center

    Dr. Lorenzo Cohen, Director of the Integrative Medicine Program at The University of Texas MD Anderson Cancer Center. He's also co-lead author of a study on whether biofield therapy can impact pancreatic cancer. The study demonstrated that biofield therapy could decrease cancer cell proliferation, disrupt mitochondrial function, and reduce metastasis in both cell cultures and animal models, with results comparable to chemotherapy without the side effects. He highlights the challenges to the wider acceptance of this therapy, given the lack of understanding of its mechanism of action and awareness about this growing area of integrative medicine. Lorenzo explains, "So biofield therapies fall into this category of, let's call them treatment modalities in the field of integrative medicine. So integrative medicine can be things like acupuncture, massage, yoga, meditation, nutrition counseling, exercise, things that you could say fall outside of the conventional traditional medical treatments that are within hospital systems. Now, integrative medicine as a whole and integrative oncology in particular have had a huge uptake in hospital systems because of the evidence base in those areas that I just described. The one area that probably remains the most controversial is this area of biofield therapies or often known as energy medicine. I don't actually really like using the term energy medicine because that implies that we know it has something to do with energy, and we're actually not sure exactly what the mechanism is of these therapies. And so what are these? So many of the listeners will have heard of things like Reiki, healing touch, or therapeutic touch."   "External Qigong falls into this category. These are modalities where a practitioner has been trained to be able to work with their own consciousness or their own intention, potentially the biofield of their body. And it is not controversial to know that we as human beings are energetic beings, and we actually do emit biophotons by the nature of being human. But the controversial part is that they are doing that towards a target, whether that be a human being, or, in our case, cells or animals in a laboratory.  And we, in particular, worked with a biofield therapy called the Bengston Cycling Method." #MDAnderson #IntegrativeOncology #BiofieldTherapy #PancreaticCancer #Metastasis #FOXM1 #Mitochondria #PreclinicalResearch #EnergyMedicine #OncologyResearch.  Biofield Therapy Anticancer Living: Transform Your Life and Health with the Mix of Six Download the transcript here

    22 min

  6. 2d ago ·  Bonus

    Accelerating Drug Development for Rare Kleefstra Syndrome with Geoff Rhyne IDefine TRANSCRIPT

    Geoff Rhyne, Co-Founder and CEO of IDefine, discusses the mission to advance research into Kleefstra syndrome, a rare genetic disorder, and to find a treatment where there is currently none. This organization of parents of children with KS is advocating for broader genetic sequencing to identify KS patients and differentiate the condition from other possible diagnoses, such as autism. Their research strategy is to first build the necessary infrastructure, including real-world data, model systems, and clinical guidelines, to de-risk the process for researchers and directly fund drug development. Geoff explains, "We're dedicated to advancing research, building community, and driving progress for Kleefstra syndrome. And the inspiration behind it is that a bunch of parents had impacted children. And, namely, for me, my daughter Ella received her diagnosis on February 26th, 2019. You asked a rare disease parent. Their diagnosis day and odds are they'll be able to rattle off pretty quickly because it is life-altering and changing. And once we looked around the landscape of Kleefstra syndrome and what was being done, we identified a need. And so a group of other parents and I came together and founded the organization in 2020."   "KS is one of these rare genetic disorders, and it affects brain development and basically every aspect of a child's life. And it could encompass developmental delays, feature delays, seizures, kidney issues, and cascading other conditions. So what happens with KS is that when you get the diagnosis, folks have often gone on a diagnostic odyssey. It's very rare that folks are being identified early on. And so we're part of that cohort that believes there are many more patients out there with KS, but the diagnostic odyssey is a real challenge. And so we typically will see kids receiving their diagnosis from three years to we've had someone diagnosed at 40 before, which is just a crazy experience as you can imagine." #IDefine #KleefstraSyndrome #EHMT1 #RareDisease #RareDiseaseResearch #NeurodevelopmentalDisorders #GeneticDisorders #PatientAdvocacy #CaregiverSupport #FamilyLedResearch #RareDiseaseCommunity #PrecisionMedicine #Genomics #MedicalResearch #ClinicalResearch #TranslationalResearch #DiagnosticJourney #PatientSupport #ResearchFunding #InclusiveCare #PatientVoices #RareDiseaseAwareness IDefine.org Listen to the podcast here

  7. 2d ago

    Accelerating Drug Development for Rare Kleefstra Syndrome with Geoff Rhyne IDefine

    Geoff Rhyne, Co-Founder and CEO of IDefine, discusses the mission to advance research into Kleefstra syndrome, a rare genetic disorder, and to find a treatment where there is currently none. This organization of parents of children with KS is advocating for broader genetic sequencing to identify KS patients and differentiate the condition from other possible diagnoses, such as autism. Their research strategy is to first build the necessary infrastructure, including real-world data, model systems, and clinical guidelines, to de-risk the process for researchers and directly fund drug development. Geoff explains, "We're dedicated to advancing research, building community, and driving progress for Kleefstra syndrome. And the inspiration behind it is that a bunch of parents had impacted children. And, namely, for me, my daughter Ella received her diagnosis on February 26th, 2019. You asked a rare disease parent. Their diagnosis day and odds are they'll be able to rattle off pretty quickly because it is life-altering and changing. And once we looked around the landscape of Kleefstra syndrome and what was being done, we identified a need. And so a group of other parents and I came together and founded the organization in 2020."   "KS is one of these rare genetic disorders, and it affects brain development and basically every aspect of a child's life. And it could encompass developmental delays, feature delays, seizures, kidney issues, and cascading other conditions. So what happens with KS is that when you get the diagnosis, folks have often gone on a diagnostic odyssey. It's very rare that folks are being identified early on. And so we're part of that cohort that believes there are many more patients out there with KS, but the diagnostic odyssey is a real challenge. And so we typically will see kids receiving their diagnosis from three years to we've had someone diagnosed at 40 before, which is just a crazy experience as you can imagine." #IDefine #KleefstraSyndrome #EHMT1 #RareDisease #RareDiseaseResearch #NeurodevelopmentalDisorders #GeneticDisorders #PatientAdvocacy #CaregiverSupport #FamilyLedResearch #RareDiseaseCommunity #PrecisionMedicine #Genomics #MedicalResearch #ClinicalResearch #TranslationalResearch #DiagnosticJourney #PatientSupport #ResearchFunding #InclusiveCare #PatientVoices #RareDiseaseAwareness IDefine.org Download the transcript here

    23 min

  8. 3d ago ·  Bonus

    Smart Mini Robots and Biomimetic Mitral Valves Set to Transform Advanced Cardiac Care with Dr. Philippe Pouletty Carvolix TRANSCRIPT

    Philippe Pouletty, M.D., CEO of Truffle Capital and Founder of Carvolix, describes the evolution of heart valve replacement and the significance of AI-guided robotics in expanding access to transcatheter procedures. The company's biomimetic mitral valve and AI software that guides valve placement using a mini robot are making these procedures safer and easier for less experienced cardiologists to perform.  The technology is also being adapted to treat brain strokes by enabling a larger pool of cardiologists to quickly perform necessary interventions. Philippe explains, "At Truffle Capital, are what we like to call ourselves Business Builders, which is to say we're not just going to start small companies, we are going to try and build world leaders to revolutionize medicine. For Carvolix, this means interventional cardiology as well as the treatment of brain strokes. As you know, replacing heart valves is a major medical need. We have four heart valves that open and close 50 to 100 times per minute, which can get calcified and dysfunctional with time and need replacement. So 40 years ago, you would go to a skilled surgeon who would say, "Okay, I'm going to open your chest. I'm going to stop your heart, and I'm going to sew a new valve."   "But recently we decided to lead the new revolution, which is a small robot based on artificial intelligence, that could autonomously, under the clinical supervision of a cardiologist, replace a valve. We think that this new revolution is going to allow many more patients to benefit from aortic, mitral, and tricuspid valve replacement, even in smaller cardiac centers and among younger cardiologists. A similar revolution happened in the cockpit of Boeing and Airbus planes when the autopilot, the GPS systems, and satellite systems brought autonomy to planes." #Carvolix #CardiacNews #PatientCare #HealthTech #Cardio #AIinHealthcare #InterventionalCardiology #StrokeCare #MedTechInnovation #RoboticsInMedicine #TAVI #Thrombectomy #DigitalHealth Carvolix.eu Listen to the podcast here

See All (2K)

4.9
out of 5
18 Ratings

About

Empowered Patient Podcast with Karen Jagoda is a window into the latest innovations in digital health, the changing dynamic between doctors and patients, and the emergence of precision medicine. The show covers such topics as aging in place, innovative uses for wearables and sensors, advances in clinical research, applied genetics, drug development, and challenges for connected health entrepreneurs.

Information